Back to today’s briefing

Story perspectives

Cerebral Palsy Market Poised for Growth Through 2034

4/3/2025

31 4

Summary

Story summary

The Cerebral Palsy market is set for remarkable growth between 2024 and 2034, fueled by groundbreaking therapies and advancements in genetic testing. In 2023, the US reported nearly 932,000 diagnosed cases, highlighting the urgent need for effective solutions. Leading companies like Neurocrine Biosciences and Teva Pharmaceuticals are at the forefront, dedicated to transforming patient care.

1 of 1

Story summary

The Cerebral Palsy market is set for remarkable growth between 2024 and 2034, fueled by groundbreaking therapies and advancements in genetic testing. In 2023, the US reported nearly 932,000 diagnosed cases, highlighting the urgent need for effective solutions. Leading companies like Neurocrine Biosciences and Teva Pharmaceuticals are at the forefront, dedicated to transforming patient care.